Emergent BioSolutions Looks to Break $1 Billion

Emergent BioSolutions (NYSE: EBS) wrapped up the year with a solid increase in fourth-quarter revenue, driven by new products it acquired over the last year. Timing of shipments of its bioterrorism defense products also affected the year-over-year comparison.